Skip to main content

Table 1 Included drugs and trials

From: Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications—a methodological review

Drug name

Number of trials

Pharmaceutical company

Type of cancer

Trial name available

Afatinib

6

Boehringer Ingelheim

Head and neck squamous cell carcinoma, non-small cell lung cancer

LUX-Head and Neck 1, LUX-Lung 5, LUX-Lung 6, LUX-Lung 8, LUX-LUNG 1

Bevacizumab

6

Roche

Non-small cell lung cancer

ATLAS, EURTAC, BeTa

Cabozantinib

4

Exelixis

Medullary thyroid cancer, renal cell carcinoma, prostate cancer

EXAM, METEOR, COMET-1, COMET-2

Cediranib

5

AstraZeneca

Ovarian cancer, colorectal cancer, renal cell carcinoma, glioblastoma

ICON6, HORIZON III, HORIZON II, REGAL

Cediranib

2

NCIC Clinical Trials Group

Non-small cell lung cancer

 

Erlotinib

1

Roche

Non-small cell lung cancer

 

Everolimus

1

Novartis

Neuro-endocrine tumour (gastro-intestinal or lung origin)

RADIANT-4

Lenvatinib

4

Eisai

Non-small cell lung cancer, glioma, differentiated thyroid cancer, hepatocellular carcinoma

SELECT

Nivolumab

4

Bristol-Myers Squibb

Renal cell carcinoma, non-small cell lung cancer, melanoma

CheckMate 025, CheckMate 057, CheckMate 067, Checkmate 069

Olaratumab

3

ImClone Systems

Ovarian cancer, non-small cell lung cancer, prostate cancer

 

Palbociclib

3

Pfizer

Breast cancer

PALOMA-2, PALOMA-3, PALOMA-4

Pembrolizumab

3

Merck

Melanoma, non-small cell lung cancer

Keynote-006, Keynote-010, Keynote-024